Chemical Property of Mifepristone
Chemical Property:
- Appearance/Colour:pale yellow solid
- Vapor Pressure:1.14E-16mmHg at 25°C
- Melting Point:195-198 °C
- Refractive Index:1.623
- Boiling Point:628.6 °C at 760 mmHg
- PKA:12.94±0.60(Predicted)
- Flash Point:334 °C
- PSA：40.54000
- Density:1.18 g/cm3
- LogP:5.40650
- Storage Temp.:2-8°C
- Solubility.:Soluble in DMSO (up to 40 mg/ml) or in Ethanol (up to 20 mg/ml).
- Water Solubility.:474.8ug/L(22.5 oC)
- XLogP3:3.8
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:3
- Rotatable Bond Count:3
- Exact Mass:429.266779359
- Heavy Atom Count:32
- Complexity:921
- Purity/Quality:
-
98.0%min *data from raw suppliers
Mifepristone ≥99%(HPLC) *data from reagent suppliers
Safty Information:
- Pictogram(s):
T
- Hazard Codes:T
- Statements:
60-61
- Safety Statements:
53-22-36/37/39-45
- MSDS Files:
-
SDS file from LookChem
Useful:
- Drug Classes:Pregnancy Termination Agents
- Canonical SMILES:CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O
- Isomeric SMILES:CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O
- Recent ClinicalTrials:Mifepristone for Labor Induction
- Recent EU Clinical Trials:REStoring mood after Early life Trauma – Glucocorticoid Receptor (GR) blockade as disease-modifying treatment for depression with childhood trauma
-
Description
Mifepristone is a kind of antagonist of the progestational and glucocorticoid hormone. It is mainly used for the treatment of hypercortisolism in patients with nonpituitary cushing syndrome. During the treatment of Cushing’s syndrome, mifepristone takes effect through interfering with the binding of cortisol to its receptor. It reduces the effects of excess cortisol (e.g., high blood sugar levels) without causing decreased cortisol production. It can also be used to end a pregnancy. Its inhibition on progesterone can induce bleeding during the luteal phase and in early pregnancy. Mifepristone is an orally-active progesterone and glucocorticoid receptor antagonist
indicated for use as a post-coital contraceptive. In addition to being an abortifacient,
mifepristone is reported to be effective in the treatment of ocular hypertension; its
potential therapeutic effect in hormone-dependent tumors is currently under investigation.
-
Uses
glutamate uptake inhibitor, AMPA blocker A progesterone and glucocorticoid antagonist, suppresses VEGF production. A progesterone receptor antagonist with partial agonist activity. Abortifacient. Mifepristone is a progesterone receptor antagonist with partial agonist activity. Abortifacient.
-
Indications
Mifepristone is a progesterone receptor antagonist that
has a high affinity for glucocorticoid receptors and little
agonist effect.This drug has recently been approved for
use in the United States for the treatment of hypercortisolism.
At high doses, mifepristone blocks negative
feedback of the hypothalamic–pituitary axis, thereby increasing
endogenous corticotrophin and cortisol levels.
Because mifepristone exerts its effects at the receptor
level and not by altering glucocorticoid production, elevated
serum cortisol and corticotrophin levels may not
accurately reflect the effectiveness of the therapeutic
regimen. Mifepristone does not inhibit cortisol binding
to the mineralocorticoid receptor, so that the resulting
corticotrophin disinhibition may cause potassium depletion.
Thus, administration of a mineralocorticoid receptor
antagonist such as spironolactone may be indicated
with mifepristone. Hypoadrenalism, nausea, and
drowsiness have been reported during prolonged administration
of mifepristone.
-
Therapeutic Function
Antiprogesterone
-
Clinical Use
An antiprogestin is a substance that competes with progesterone for its receptor and, ultimately, prevents progesterone from binding to and activating its receptor. Because progesterone is integral to the continuation of an early pregnancy, it is expected that antipro-gestins will interfere with pregnancy maintenance. In 1982, the first antiproges tin, mifepristone (RU 486), was reported. Mifepristone was shown to interrupt early stages of implantation and pregnancy in humans.
